No Data
No Data
Express News | NeurAxis Submits To FDA For Expansion Of IB-Stim Label; Provides Compliance With NYSE Guidelines
Express News | Neuraxis Inc: New Submission to FDA to Expand Label for Ib-Stim Which Would Include Ages 8-21, and 4 Devices Over 4 Weeks
Express News | Neuraxis Announces New Submission to the FDA for the Expansion of Its Ib-Stim Label; Provides Compliance With NYSE Guidelines on Audit Disclosure
Earnings Call Summary | Neuraxis(NRXS.US) Q1 2024 Earnings Conference
The following is a summary of the NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript:Financial Performance:NeurAxis generated a Q1 revenue of $646,000 from 222 patient treatments, showing high dem
Neuraxis Q1 2024 GAAP EPS $(0.32) Up From $(1.18) YoY, Sales $646.635K Miss $2.229M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.32) per share. This is a 72.88 percent increase over losses of $(1.18) per share from the same period last year. The company reported quarterly s
Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635
08:02 AM EDT, 05/22/2024 (MT Newswires) -- Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635
No Data